Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY-NC-NDJournal of Proteome Research

Advancing Host Cell Protein Characterization in Monoclonal Antibody Therapeutics: A Nanoparticle-Enriched and High-Sensitivity Mass Spectrometry Approach

  1. 1School of Pharmacy and Biomedical Science, Centre for Pharmaceutical Innovation, College of Health, Adelaide University, Adelaide, SA 5000, Australia
  2. 2CSL Innovation, Melbourne, VIC 3000, Australia
  3. 3Mass Dynamics, Melbourne, VIC 3000, Australia

Abstract

Host cell protein (HCP) characterization in monoclonal antibody (mAb) products is challenged by a large concentration gap between low-abundance HCPs and high-abundance mAb proteins. Advances in sample preparation, chromatography, and mass spectrometry techniques have aimed at either reducing this concentration imbalance or the peptide coelution effects during chromatography. Despite this, comprehensive characterization of HCPs remains difficult, particularly at below-ppm levels, often requiring complex and low-throughput methodologies. This study presents a rapid, sensitive, and high-throughput HCP characterization workflow integrating the Seer Proteograph XT nanoparticle-enrichment platform, the Evosep ONE LC system, and timsUltra AIP mass spectrometer. This workflow enables efficient sample preparation (accommodating 40-sample digestions: 20 mAb samples within 6 h) and a 40-sample-per-day LC-MS method. Using a dynamic protein standard, the method achieved a lowest reproducible protein spike-in of 0.2 ppm, outperforming the native digestion approach (∼1 ppm). Application to NISTmAb 8671, identified over 350 HCPs, including those at sub-ppm levels, confidently and reproducibly. Furthermore, analysis of three commercial products identified 80-200 additional HCPs undetected by native digestion. Overall, our results highlight the potential of automated nanoparticle enrichment and advanced mass spectrometry for high-throughput, sensitive, and reproducible detection of low-level HCPs, enabling rapid risk assessment and improved biopharmaceutical purification strategies.

Related

  1. Direct infusion intact mass spectrometry for rapid and sensitive characterization of antibody therapeutics in complex matrices
    Dan Bach Kristensen, Alain Beck, Clara Coll-Satue +8
    mAbsPeer-reviewedCC BY-NC 4.0Full textPhysical chemistryPMC
  2. Rapid peptide mapping of monoclonal antibodies with direct infusion mass spectrometry
    Austin Z. Salome, Marcel Morgenstern, Alexander S. Hebert +18
    Communications ChemistryPeer-reviewedCC BY 4.0General chemistryNatureCrossref
  3. Quantitative Cryogenic Orbitrap Secondary Ion Mass Spectrometry for structural characterization of lipid nanoparticles
    Joseph W Roberts, Anna Kotowska, Eduardo Aguilar-Bejarano +13
    ChemRxivPreprintLicence not statedGeneral chemistryChemRxiv
  4. Accelerated characterization of active natural extracts with single-step microfractionation coupled to mass spectrometry and bioassays
    Joshua Smith, Erik Bouchal, Zdeněk Knejzlík +16
    ChemRxivPreprintLicence not statedGeneral chemistryChemRxiv
  5. Stereospecific Characterization of Triacylglycerols in Vegetable Oils by Chiral Supercritical Fluid Chromatography and Mass Spectrometry
    Marika Kalpio, Dilakshi Naotunna Palliya Guruge, Mikael Fabritius +2
    Journal of Agricultural and Food ChemistryPeer-reviewedCC BY 4.0Full textAnalytical chemistryPMC
BibTeX
@article{akinloye2026advancing,
  title = {{Advancing Host Cell Protein Characterization in Monoclonal Antibody Therapeutics: A Nanoparticle-Enriched and High-Sensitivity Mass Spectrometry Approach}},
  author = {Abdulafeez Akinloye and Sri Ramarathinam and Parul Mittal and Daniel Pincher and Leigh Donnellan and Clifford Young and Lee Xin Chong and Rhys Wyber and Mark R. Condina and Alok K. Shah and Peter Hoffmann},
  journal = {Journal of Proteome Research},
  year = {2026},
  month = oct,
  doi = {10.1021/acs.jproteome.6c00666},
  url = {https://doi.org/10.1021/acs.jproteome.6c00666},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Advancing Host Cell Protein Characterization in Monoclonal Antibody Therapeutics: A Nanoparticle-Enriched and High-Sensitivity Mass Spectrometry Approach
AU  - Abdulafeez Akinloye
AU  - Sri Ramarathinam
AU  - Parul Mittal
AU  - Daniel Pincher
AU  - Leigh Donnellan
AU  - Clifford Young
AU  - Lee Xin Chong
AU  - Rhys Wyber
AU  - Mark R. Condina
AU  - Alok K. Shah
AU  - Peter Hoffmann
PY  - 2026
DA  - 2026/10/13
JO  - Journal of Proteome Research
DO  - 10.1021/acs.jproteome.6c00666
UR  - https://doi.org/10.1021/acs.jproteome.6c00666
AB  - Host cell protein (HCP) characterization in monoclonal antibody (mAb) products is challenged by a large concentration gap between low-abundance HCPs and high-abundance mAb proteins. Advances in sample preparation, chromatography, and mass spectrometry techniques have aimed at either reducing this concentration imbalance or the peptide coelution effects during chromatography. Despite this, comprehensive characterization of HCPs remains difficult, particularly at below-ppm levels, often requiring complex and low-throughput methodologies. This study presents a rapid, sensitive, and high-throughput HCP characterization workflow integrating the Seer Proteograph XT nanoparticle-enrichment platform, the Evosep ONE LC system, and timsUltra AIP mass spectrometer. This workflow enables efficient sample preparation (accommodating 40-sample digestions: 20 mAb samples within 6 h) and a 40-sample-per-day LC-MS method. Using a dynamic protein standard, the method achieved a lowest reproducible protein spike-in of 0.2 ppm, outperforming the native digestion approach (∼1 ppm). Application to NISTmAb 8671, identified over 350 HCPs, including those at sub-ppm levels, confidently and reproducibly. Furthermore, analysis of three commercial products identified 80-200 additional HCPs undetected by native digestion. Overall, our results highlight the potential of automated nanoparticle enrichment and advanced mass spectrometry for high-throughput, sensitive, and reproducible detection of low-level HCPs, enabling rapid risk assessment and improved biopharmaceutical purification strategies.
SN  - 1535-3893
SN  - 1535-3907
ER  -